Abbott Exercises Option to Buy Cephea Valve Technologies
January 16 2019 - 9:51AM
Dow Jones News
By Colin Kellaher
Abbott Laboratories (ABT) on Wednesday said it exercised its
option to buy medical-device company Cephea Valve Technologies Inc.
for an undisclosed amount.
The Abbott Park, Ill., maker of healthcare products said Cephea
is developing a less-invasive heart-valve replacement technology
for patients with mitral-valve disease.
Abbott provided capital to privately held Cephea and secured an
option to buy the company in 2015.
Mitral-valve disease is the most common heart-valve problem,
affecting more than four million people in the U.S. alone, Abbott
said.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 16, 2019 09:36 ET (14:36 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Apr 2023 to Apr 2024
